Ultra Processed Foods Consumption and Impact in Rheumatic Diseases.
Launched by HOSPICES CIVILS DE LYON · Jan 10, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the impact of ultra-processed foods (UPF) on people with certain rheumatic diseases, such as rheumatoid arthritis, spondyloarthritis, and osteoarthritis. UPFs are foods that are heavily processed and often contain artificial ingredients. Researchers want to understand how eating these types of foods might be linked to the activity and severity of rheumatic diseases. They are particularly interested in whether UPF consumption can affect the immune system and gut health, which are important in these conditions.
To participate in the study, individuals must be over 18 years old and have a chronic rheumatic disease. They should also be able to complete questionnaires about their eating habits and health. Unfortunately, those who are under legal protection or have more than one rheumatic disease at the same time cannot join. If you take part, you will be asked about your diet and how it relates to your health, helping researchers learn more about the connection between diet and rheumatic diseases. This could lead to better dietary recommendations for people living with these conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years
- • chronic rheumatic disease (Rheumatoid arthritis, spondyloarthritis, osteoarthritis)
- • ability to perform questionnaires
- Exclusion Criteria:
- • Judicial protection measure
- • Refusal to participate in the study
- • Suffering from 2 rheumatic disease simultaneously
About Hospices Civils De Lyon
Hospices Civils de Lyon (HCL) is a leading public health institution in France, dedicated to providing high-quality healthcare and advancing medical research. With a rich history dating back to the 18th century, HCL encompasses multiple hospitals and offers a diverse range of services across various medical specialties. The institution is committed to fostering innovative clinical trials that aim to enhance patient care and improve therapeutic outcomes. By collaborating with academic and industry partners, HCL plays a pivotal role in the development of new treatments and the advancement of medical knowledge, ensuring that research efforts are aligned with the highest ethical standards and patient safety protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lyon, , France
Patients applied
Trial Officials
Maxime AUROUX, MD
Principal Investigator
Edouard Herriot Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported